Patients are encouraged to discuss the risks, benefits, and appropriateness of any medications, including compounded products, with their healthcare provider before use
Symptoms may raise suspicion, but testing helps confirm delayed emptying and exclude other causes
This approach helps bridge the gap between expectation and reality, ensuring you are fully informed about your purchase
After 104 weeks of treatment, the primary outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.6% of the patients in the semaglutide group and 8.9% of those in the placebo group, resulting in a hazard ratio (HR) of 0.74 (95% CI 0.580.95) [13]
Ashley Koff, RD 00:32:05 Yeah, I think its okay